Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.36 |
| ▸ | CDK1 | P06493 | 5/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.36 |
| ▸ | MDH2 | P40926 | 5/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925855 | 0.86 | CDK1 (0.46) | PRKCAMMP12NR1I2CCNB2CDK1 | |
| SCHEMBL14435330 | 0.84 | PRKCA (0.43) | PRKCAMMP12NR1I2CCNB2CDK1 | |
| SCHEMBL874916 | 0.84 | PRKCA (0.50) | PRKCAMMP12NR1I2CCNB2CDK1 | |
| SCHEMBL14435944 | 0.83 | SCN9A (0.43) | PRKCAMMP12NR1I2SCN9A | |
| SCHEMBL3576170 | 0.78 | CREBBP (0.46) | PRKCAMMP12NR1I2CCNB2CDK1 | |
| SCHEMBL14253194 | 0.77 | SCN9A (0.62) | NR1I2SCN9A | |
| SCHEMBL792582 | 0.77 | CCNB2 (0.39) | PRKCAMMP12NR1I2CCNB2CDK1 | |
| SCHEMBL5256403 | 0.77 | OPRM1 (0.39) | CCNB2CDK1CCNB1CCNB3GSK3B | |
| SCHEMBL923845 | 0.77 | NR1I2 (0.44) | PRKCAMMP12NR1I2CCNB2CDK1 | |
| SCHEMBL14253262 | 0.76 | NR1I2 (0.62) | PRKCAMMP12NR1I2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431568-B2 | Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2278977-B1 | AROMATIC HETEROCYCLIC FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110014154-A1 | Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014154-A1 | Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors | HAVCR2, NSD2, ZC3HAV1 | PRKCA 3911/4885MMP12 4743/4885NR1I2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.